Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Non-invasive Coronary Functional Tests in ANOCA
Author(s): Nello Cambise , Angelo Giuseppe Marino , Fabio De Benedetto , et al Added: 3 months ago

Imaging & Diagnostics

Prevention & Chronic Conditions
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 1 year ago

Prevention & Chronic Conditions
The Coronary Microcirculation Re-explored
Author(s): Ahmed Elamin , Mustafa Abdimalik , Mohanad Abdelrahim , et al Added: 6 months ago

Prevention & Chronic Conditions
Updates on Chronic Coronary Syndrome
Author(s): Filippo Gurgoglione , Giampaolo Niccoli Added: 1 year ago

Prevention & Chronic Conditions

CV Disease in Special Populations
ECG Exercise Stress Test in Coronary Artery Disease
Author(s): Gaetano Antonio Lanza Added: 11 months ago

Guidelines & Statements
30th Annual Meeting of the ISCP
Author(s): Andrés Álvarez , Diego Manuel de la Eranueva , Manuel Sánchez , et al Added: 1 month ago

Prevention & Chronic Conditions
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 1 year ago

Prevention & Chronic Conditions
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 8 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 1 year ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention
Left Main Disease: The Last Frontier for Medical Therapy in Stable CAD?
Author(s): Armin Arbab-Zadeh , Michelle Graham , Hector M Garcia-Garcia , et al Added: 8 months ago

Intervention

Prevention & Chronic Conditions